Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
    • Heat Biologics Mask
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics Provides Clinical and Business Update

Jan 10, 2019

Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 8, 2019

Heat Biologics to Present at Biotech Showcase 2019 in California

Jan 4, 2019

Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering

Nov 26, 2018

Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum

Nov 26, 2018

Heat Biologics, Inc. Prices $12,000,000 Public Offering

Nov 21, 2018

Heat Biologics, Inc. Announces Proposed Public Offering

Nov 20, 2018

Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update

Nov 15, 2018

Heat Biologics to Present at Precision: Lung Cancer World R&D Summit

Oct 22, 2018

Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City

Oct 19, 2018
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...25
    © 2021 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn